Novo Nordisk Sues Two U.S. Pharmacies Over Counterfeit Semaglutide Weight-Loss Drugs

On November 30 local time, Novo Nordisk’s U.S. company announced that, as part of its ongoing commitment to patient safety, it is taking several additional legal actions to protect American patients and consumers from adulterated drugs sold by two pharmacies, Wells Pharmacy Network and Brooksville Pharmaceuticals, which claim to contain semaglutide. (Jiemian)Original Link